The GZF1 Knockout SK-HEP-1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout population targeting the GZF1 locus in the SK-HEP-1 human liver adenocarcinoma cell line. This engineered model disrupts GZF1 gene function, offering a versatile loss-of-function system to study the transcription factor??s contributions to hepatocellular carcinoma biology. The polyclonal design preserves editing heterogeneity, circumventing clonal artifacts and representing a more physiologically relevant knockout model for investigating gene regulation in cancer.
SK-HEP-1 cells were derived from the ascites of a patient with liver adenocarcinoma and feature a hypertriploid karyotype, modeling the chromosomal instability prevalent in advanced liver malignancies. This line is widely utilized in oncology research as a surrogate for hepatic adenocarcinoma and hepatocellular carcinoma, enabling analysis of tumor cell proliferation, migration, invasion, and responsiveness to therapeutic agents. Its mesenchymal phenotype further supports studies on epithelial-to-mesenchymal transition (EMT) and metastatic progression.
GZF1 is a BTB/POZ domain-containing zinc finger protein that functions as a transcriptional repressor and activator depending on context. In hepatocellular carcinoma, GZF1 predominantly enhances Wnt/??-catenin signaling by directly binding and repressing the promoter of the Wnt antagonist SFRP1, thereby increasing ??-catenin/TCF4?Cdriven transcription of oncogenic targets such as CCND1. GZF1 forms complexes with corepressors NCoR and SMRT, and interacts physically with ??-catenin and TCF4. Its expression is stimulated by GDNF/RET signaling and the ??-catenin/TCF complex, establishing a positive regulatory loop. Additionally, GZF1 modulates expression of BCL2 family members and matrix metalloproteinases (MMPs), implicating it in apoptosis evasion and invasive behavior.
In the SK-HEP-1 background, GZF1 knockout disrupts repression of SFRP1, leading to attenuation of Wnt/??-catenin signaling and consequent reductions in proliferative and invasive capacities. This model therefore permits detailed interrogation of GZF1-dependent oncogenic pathways, including EMT, extracellular matrix remodeling, and survival signaling, within a heterogeneous polyclonal population that mirrors the genetic diversity observed in tumors. The knockout cells serve as a stringent platform for validating GZF1 as a therapeutic target in liver and related cancers.
Researchers can employ these cells in a range of downstream assays: transcriptome profiling by RNA-seq, chromatin occupancy analysis via ChIP-qPCR, and Wnt pathway activity measurement with TOP/FOP flash reporters. Functional assays including proliferation, migration, and invasion experiments directly correlate GZF1 ablation with phenotypic outcomes, while co-immunoprecipitation studies characterize altered protein interactions. The model is well-suited for drug target validation campaigns and high-throughput screens for modulators of GZF1-dependent signaling. For additional information or technical support, please contact Ascent Research.
